News

Veryan closes £3.6m funding round to develop novel BioMimics 3D stent technology and announces the commencement of first-in human studies

Veryan Holdings Limited (“Veryan”) announced today that it has secured additional funding totaling £3.6 million (US $5.4 million) from a syndicate of Investors led by new investor Seroba Kernel, a European life science venture capital firm, alongside existing investors Imperial Innovations, Oxford Capital Partners Limited and NESTA. The funds will be employed to finance further development activities and a pivotal clinical trial designed to show the clinical benefit of Veryans’ unique BioMimics 3D™ stent technology.

Veryan technology

Peripheral vascular disease treatment is one of the fastest growing segments of the cardiovascular device market, the potential market value is in excess of $1 billion. Existing stent technologies have demonstrated significant performance shortfalls including restenosis (re-narrowing) and inadequate mechanical performance leading to suboptimal clinical results.

Veryan is developing a novel ...Read entire article

Business XL Award

The Business XL and GP Bullhound Investor AllStars Awards recognised the nous, nerve and acumen of some of the key players on the UK’s thriving venture capital scene. Nick Britton reports Private equity isn’t all champagne and caviar, but it certainly does have its moments
of glamour. The annual Investor AllStars Awards, held this year at London’s Park Lane Hilton, saw over 600 of Europe’s venture capital elite gather together and be acknowledged for cutting-edge deal-making over the past 12 months.

The awards were presented by BBC newsreader Emily Maitlis and recognised achievements in a range of categories, from Jon Moulton’s Triumph over
Adversity to VC Personality of the Year. Nominees included long-established global giants such as 3i as well as relative newcomers such as investors’
network Hotbed.

International Deal of the Year Winner: Sudbrook Associates LLP (Safeguard) Nominees: Nigel Weller (I-CanNano)...Read entire article

Isconova secures 30 million Swedish kronor growth financing

Isconova AB, announced today that it has secured financing of 30 million Swedish kronor ( 3,3 m€ ) from InnovationsKapital, a leading Nordic venture capital firm, and a group of private investors. Isconova is a pioneer in vaccine adjuvant technology, with a proprietary, safe and effective ISCOM technology.

"We are extremely pleased to have attracted the support of InnovationsKapital, who have a successful record of backing innovative growth biotech companies in Scandinavia. This new investment will allow Isconova to increase our production capacity and to invest in marketing,” said Bengt Falk, Isconova’s CEO. “It will enable us to build on our existing growth in the animal vaccine sector. We will also be able to accelerate our activities in human vaccines where we already have a very promising partnership on an influenza vaccine."

Isconova’s scientific excellence in the vaccine adjuvant field is backed by commercial validation t...Read entire article

Innocoll Announces Closing of $30 Million Equity Financing Investment

ASHBURN, Va.,December 17, 2007 /PRNewswire/ –– Innocoll, Inc., a privately held specialty pharmaceutical company, announced that it has closed an equity financing investment to raise $30 million through the sale of convertible preferred stock in a private placement with three institutional investors led by Camulos Capital LP together with NewSmith Asset Management LLP and Morgan Stanley & Co, Incorporated. The existing principal shareholders, Rolf and William Schmidt, also converted existing loans totalling approximately $16 million into convertible preferred stock. The financing will be used to fund a series of phase 2 and phase 3 clinical trials for Innocoll’s lead product development programs, payment of financing fees, and general corporate purposes.

Commenting on the equity financing, Dr. Michael Myers, President and CEO said, “We are delighted to have attracted three institutional investors of the calibre of Camulos, NewSmith and Morgan Stan...Read entire article